THE APEX TIMES
After posting 39% year-over-year revenue growth in the third quarter, Eli Lilly reported momentum in Mounjaro and Zepbound even as Medicare’s GLP-1 Bridge program begins to pressure drug pricing.
Eli Lilly’s first full quarter tied to Medicare’s expanding coverage framework put a familiar tension front and center for weight-loss and diabetes drugs: if reimbursement starts to come with lower prices, can sales growth still ride on higher volume. In a recent market report, the company pointed to continued strength in Mounjaro and Zepbound, suggesting demand has not been crowded out by the coming pricing changes.
The report said Eli Lilly posted 39% year-over-year revenue growth in the third quarter of 2026, attributing much of the increase to strong sales of Mounjaro and Zepbound. Mounjaro is Eli Lilly’s brand for tirzepatide, a medicine approved for type 2 diabetes that helps lower blood sugar and can also drive weight reduction. Zepbound is the company’s tirzepatide product in the obesity indication, targeting weight management.
Importantly, the market coverage framed the quarter as the start of a more complete Medicare cycle for the drugs. Under Medicare’s GLP-1 Bridge program, the economics of coverage shift over time, and the report said those changes are putting pressure on drug pricing. The central debate for Lilly is whether reduced net pricing per prescription will be offset by an increase in the number of prescriptions filled as more beneficiaries gain access.
Even with that pricing headwind, the report said Eli Lilly raised its full-year guidance, a sign management believes demand remains resilient and that operating results can still grow in the near term. Guidance is the company’s outlook for the year, typically covering expected revenue and other financial targets; raising it usually indicates management sees either stronger-than-expected demand, improved mix, lower-than-expected costs, or a combination.
The report’s headline question, “is volume still outpacing price cuts,” highlights how the company’s performance may depend on the balance between two moving parts. On one side is unit growth as the patient pool expands through Medicare coverage. On the other is the effect of reimbursement-linked pricing pressure, which can reduce revenue per treatment even when prescriptions rise.
From a sector standpoint, Lilly is not operating in a vacuum. GLP-1 and related obesity medications have drawn intense policy attention because they are expensive and quickly scaling in usage. Medicare program design, including how it bridges coverage and reimbursement changes, can influence what manufacturers ultimately collect for each course of treatment. For companies like Eli Lilly, this means investors and analysts watch not just sales growth, but also the implied net pricing trend as policy rolls forward.
That said, the market report did not provide detailed figures on how Medicare-related pricing changed during the quarter, nor did it break out Medicare-specific revenue, prescription volume, or net pricing versus non-Medicare channels. It also did not specify the magnitude of the price reductions expected under the GLP-1 Bridge program or quantify how much of Lilly’s raised guidance was driven by volume gains versus other factors.
Going forward, the key items for Eli Lilly to clarify, based on what the market report raised but did not quantify, are whether prescription growth in Medicare accelerates enough to offset lower pricing and whether Lilly can sustain momentum in Mounjaro and Zepbound without margin compression. The next earnings updates will likely matter as investors try to map policy-driven pricing pressure to reported financial results, quarter by quarter.
Options pricing and recent trading expectations point to a potential double-digit move in Palantir stock by the end of the week following the company’s next quarterly report.
A reported interest in Boost Mobile would represent a bet that SpaceX can extend its satellite-based Starlink network into terrestrial wireless, challenging major carriers including AT&T, T-Mobile, and Verizon.
A fresh Wall Street rating upgrade points to growing confidence in Visa’s earnings trajectory, a development that investors often watch for near-term sentiment shifts.
A new market comparison highlights a stark contrast between GE Aerospace’s reported cash generation and SpaceX’s reported cash burn, while noting that GE still trades at a valuation discount.
Shares of Amazon rose about 5% following results that initially disappointed, while Walmart increased roughly 2% and Alphabet edged higher, according to market coverage. Traders appeared to concentrate less on the quarter itself and more on whether Amazon Web Services can sustain profit momentum.
Alphabet’s Google is updating the home-screen look of three core communication apps with a sharper, more unified visual style. The company says the change is cosmetic and does not alter functionality.
A reported move by Meta to tap international bond markets highlights how investors are calibrating risk as major technology spenders face tougher questions about timelines and returns.
In a move tied to artificial-intelligence spending, Alphabet’s Google unit is reportedly offering 19-year bonds to help finance additional investments.
Analysts on Starbucks’ Q3 call pressed management on what caused a year-over-year revenue miss and how the company’s shifting China operations will affect near-term sales and momentum.
The farm equipment maker said it has brought back roughly 1,000 employees since 2024 as it rebuilds production staffing following a failed contract renewal with the United Auto Workers that unraveled in August.
